SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)
| Valuation | |
|---|---|
| Market Cap ($M) | 5.74 |
| Enterprise Value ($M) | 5.74 |
| Book Value ($M) | 0.00 |
| Book Value / Share | 0.00 |
| Price / Book | n/a |
| NCAV ($M) | 0.00 |
| NCAV / Share | 0.00 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | n/a |
| Return on Assets (ROA) | -0.72 |
| Return on Equity (ROE) | -2.10 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | n/a |
| Current Ratio | n/a |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 0.00 |
| Assets | 0.00 |
| Liabilities | 0.00 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13D/A | Novalis LifeSciences Investments II, L.P. | 19.99 | -94.33 | |
| 13D/A | Northpond Ventures, LP | 47.60 | -94.36 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Similar Companies | |
|---|---|
| SYBE – Sybleu Inc. | SYRS – Syros Pharmaceuticals, Inc. |
| TBEV – High Performance Beverages Company | TCNNF – Trulieve Cannabis Corp. |
| TEVJF – Teva Pharmaceutical Industries Limited |
Financial data and stock pages provided by
Fintel.io